Choosing the right Alzheimer’s disease mouse model depends on your research goals, target pathways, your compound’s mechanism of action (MoA) and therapeutic development strategy. No single mouse model can fully replicate human Alzheimer’s disease pathophysiology, which is why model selection must be fit-for-purpose.  

Key considerations include: 

• Target pathology of your therapeutic compound: i.e., are you targeting amyloid, Tau, combined pathology, neurodegeneration and associated behavioural declines, or neuroinflammation-related targets in Alzheimer’s disease?  

• Initial aim of your study: i.e., are you searching to obtain initial proof-of-concept data to fuel further efforts or are you aiming to obtain robust preclinical efficacy data packages? Models with rapid pathology development (e.g., the Homozygous TauP301S) are often used for shorter, first-pass studies whereas models with slower pathology development (e.g., the APPxTauP301S mouse model) may be better suited for disease-modification or longitudinal studies.  

• Age of disease onset (early- vs late-onset models): Similar to the above-mentioned point, earlier onset aggressive models develop pathology within few months and are suitable for short-term efficacy or screening studies. Late-onset models may more closely resemble the age-dependent disease development and allow for a longer preventative treatment approach. In this regard, aligning the treatment start and study duration with the model’s pathology onset is critical for generating interpretable datasets supporting your transition from preclinical to clinical research.  

• Background genetics of the model associated to genetic risks of Alzheimer’s disease: Most Alzheimer’s disease mouse models are based on familial Alzheimer’s disease mutations in APP or presenilins, whereas the majority of patients have sporadic, late-onset AD. Genetic risk–based models, such as ApoE knock-in mice (particularly the  APOE4 mouse model), provide complementary insight into lipid metabolism, neuroinflammation, and risk modulation. Understanding whether a model is driven by transgene overexpression, knock-in mutations, risk alleles, or carry specific Tau isoforms helps interpret findings and anticipate translational limitations.  

A comprehensive literature review by Jankowsky et al. (2017) provides in-depth practical and mechanistic considerations for selecting Alzheimer’s disease mouse models, including the impact of APP overexpression, altered APP fragment biology, and tau isoform imbalance in Tau models. 

Beyond working with our established in-house models, InnoSer’s scientific team regularly supports the validation and implementation of sponsor-selected mouse models to ensure continuity with legacy data or internal benchmarks.  

Based on our extensive experience across Alzheimer’s disease research, InnoSer’s experts can help you identify the most appropriate mouse model(s), study design, and translational readouts for your program. 

Reach out to our team to discuss a tailored preclinical strategy for your therapeutic today. 

Many Alzheimer’s disease mouse efficacy studies, including internal validation datasets at InnoSer, have historically been carried out in female mice, primarily due to housing compatibility and reduced aggression, which enables more stable group housing and longitudinal behavioral testing.  

That said, male mice can be included where scientifically justified, and we regularly design sex-balanced studies when required by the research objective or regulatory strategy. 

Reach out to our expert neuroscience research team to discuss your study design now, including sex-balanced studies, animals required to reach statistical power and study timelines.  

What are lead times to start a study using InnoSer’s Alzheimer’s disease mouse models?  

Study lead times depend on the specific Alzheimer’s disease mouse model, age required as well as whether the mouse model is available at InnoSer or sourced and purchased via external, widely accessible laboratories.  

For InnoSer’s proprietary mouse models, InnoSer maintains aged cohorts of models, enabling rapid study initiation depending on the required animal age and genotype (if applicable). Our proactive colony planning aims to ensure that your preclinical efficacy studies can be launched with minimal lead time. 

Reach out to our study directors to discuss model availability and optimal study windows. 

Yes, InnoSer has extensive experience with performing stereotaxic surgery across multiple mouse models of neurological diseases, including Alzheimer’s disease. Stereotaxic surgery, as the name suggests, is a surgical technique frequently employed in preclinical research in rodent models of diseases to target specific brain regions to perform injections, cannula placements or electrodes for EEG studies.  

At InnoSer, stereotaxic surgery in Alzheimer’s disease mouse models is performed to administer therapeutic interventions, to perform EEG studies or to inject pathogenic seeds to establish seeding and spreading mouse models of Alzheimer’s disease and other tauopathies.  

InnoSer’s scientific study teams have optimized stereotactic coordinates for several brain regions, having experience with unilateral as well as bilateral injections. For compounds requiring repeated injections for repeated compound dosing protocols, InnoSer has significant experience in surgical techniques to implant cannulas.  

Reach out to our team to discuss your preclinical research study needs now. 

Yes, at InnoSer we offer evaluation of various blood-based and/or CSF-based biomarkers. Implementing biomarkers as part of your preclinical study readouts across multiple Alzheimer’s disease mouse models aims to facilitate the transition from preclinical to clinical research.  

Key validated, translationally relevant biomarkers that we can be evaluated in multiple Alzheimer’s disease mouse models at InnoSer include:  

• Sarkosyl-[in]soluble tau and Aβ fraction extraction 

• Quantification of total and (in)soluble biomarkers in brain lysates/ plasma/ CSF (e.g., plasma NfL, Aβ40-42, pyroglutamate-modified Aβ42,p Tau, cytokines) via ELISA/MSD  

Reach out to our expert study team to discuss the inclusion of clinically relevant biomarkers to include in your preclinical efficacy data package.